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Alternative splicing is deregulated in cancer and alternatively spliced products can
be linked to cancer hallmarks. Targeting alternative splicing could offer novel effective
cancer treatments. We investigated the effects of the crude extract of a South African
medicinal plant, Cotyledon orbiculata, on cell survival of colon (HCT116) and esophageal
(OE33 and KYSE70) cancer cell lines. Using RNASeq, we discovered that the extract
interfered with mRNA regulatory pathways. The extract caused hnRNPA2B1 to splice
from the hnRNPB1 to the hnRNPA2 isoform, resulting in a switch in the BCL2L1 gene
from Bcl-xL to Bcl-xS causing activation of caspase-3-cleavage and apoptosis. Similar
splicing effects were induced by the known anti-cancer splicing modulator pladienolide
B. Knockdown of hnRNPB1 using siRNA resulted in decreased cell viability and increased
caspase-3-cleavage, and over-expression of hnRNPB1 prevented the effect of C.
orbiculata extract on apoptosis and cell survival. The effect of the hnRNPA2/B1 splicing
switch by the C. orbiculata extract increased hnRNPA2B1 binding to Bcl-xl/s, BCL2,
MDM2, cMYC, CD44, CDK6, and cJUNmRNA. These findings suggest that apoptosis in
HCT116, OE33, and KYSE cancer cells is controlled by switched splicing of hnRNPA2B1
and BCL2L1, providing evidence that hnRNPB1 regulates apoptosis. Inhibiting this
splicing could have therapeutic potential for colon and esophageal cancers. Targeting
hnRNPA2B1 splicing in colon cancer regulates splicing of BCL2L1 to induce apoptosis.
This approach could be a useful therapeutic strategy to induce apoptosis and restrain
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cancer cell proliferation and tumor progression. Here, we found that the extract of
Cotyledon orbiculata, a South African medicinal plant, had an anti-proliferative effect
in cancer cells, mediated by apoptosis induced by alternative splicing of hnRNPA2B1
and BCL2L1.
Keywords: colorectal cancer, esophageal cancer,Cotyledon orbiculata, hnRNPA2B1, Bcl-x, caspase-3, alternative
splicing
INTRODUCTION
Colorectal cancer (CRC) and esophageal cancer (EC) are
ranked the third and eighth most common cancers worldwide,
respectively. Colorectal cancer and EC have a global mortality
rate of 5.8 and 5.3%, respectively (1, 2). In South Africa, CRC is
the fourth most common cancer, with a low survival rate of 8.1%
(3, 4). Esophageal cancer is responsible for the second highest
number of cancer-related mortalities, and has a 5 year relative
survival rate of 4% in metastatic disease (5).
Despite advances in chemotherapy for the treatment of
cancer, costs, side effects, and development of resistance
to chemotherapy are major obstacles particularly in the
global south. Most chemotherapeutic agents used to treat
colon and esophageal cancers e.g., fluoropyrimidines,
cisplatin, oxaliplatin, irinotecan, carboplatin, epirubicin,
and docetaxel have been shown to induce resistance in
cancer cells. Most of these treatments are mitotic inhibitors
focusing on either preventing cell division by inhibiting
tubule formation (e.g., docetaxel) or inducing mitotic arrest
by interfering with DNA replication (platins). Resistance to
chemotherapy has led to the search for alternative effective
treatments (6, 7).
Most regulatory genes involved in apoptosis are expressed
in different isoforms with distinct functional activity and
changes in splice site patterns play an important role in cancer
development (8). In cancer cells, the process of alternative
splicing in these regulatory genes is deregulated, contributing
to the deregulation of apoptosis, development of tumors,
progression and maintenance of cancer, and eventual metastases.
Both CRC and EC are thought to be linked to genetic and
epigenetic abnormalities resulting from deregulated alternative
splicing of apoptosis genes (9–11). Several alternative splicing
factors are overexpressed and highly mutated in different
cancer tissues (12). Additionally, changes in the splicing
patterns of various alternative splicing events were identified
in tumors demonstrating a prominent role in carcinogenesis
(10), and a potential prognostic indication (13). Developing
new pharmaceuticals that target alternative splicing may create
new therapeutic avenues for treating cancer. Various derivatives
of natural products have shown potential for altering splicing
to induce apoptosis. Examples include pladienolide B, a
splicing inhibitor produced by Streptomyces platensis with potent
cytotoxicity and antitumor activity both in cancer cell lines and
mouse xenograft models (14, 15) and isoginkgetin, a biflavonoid
isolated from Ginkgo biloba that inhibits tumor cell invasion and
splicing both in vivo and in vitro (16). A derivative of pladienolide
B is now in clinical trial for leukemia.
Medicinal plants are a source of numerous molecules
with proven cytotoxicity and can trigger different signaling
pathways in several types of cancers eventually inducing
apoptosis (17, 18). Some of these molecules/compounds include
Vinca alkaloids isolated from Catharanthus roseus and its
derivatives vinblastine, vincristine, vinorelbine, vindesine (19,
20), podophyllin toxin isolated from Podophyllum peltatum and
its derivatives teniposide and etoposide (21, 22), camptothecin
isolated from Camptotheca acuminate and its derivatives
topotecan, and irinotecan (23), and taxol isolated from
Taxus brevifolia (23), and its derivatives paclitaxel, docetaxel,
cabazitaxel (24, 25). All these drugs are widely used in first
and second line cancer therapy, and have revolutionized the
treatment of several solid tumors. Vinca alkaloids in particular
represent the only therapeutic option for patients who show
drug resistance or are not candidates for curative surgical
interventions (26, 27). These are some examples highlighting the
potential of plants as sources of anticancer drugs.
In this study, we evaluate the anticancer potential of
Cotyledon orbiculata extract and use RNASeq to determine the
primary mechanism of action. We identified that apoptosis and
alternative splicing were key differentially regulated pathways
as analyzed by gene ontology analysis, with RNA regulatory
pathways being the primary pathway identified for all five types
of alternative splicing. We therefore assessed the effect of the
extract on global differential splicing (canonical and de novo) and
identified significant changes in cancer related genes. Focusing
on the effects on splicing of hnRNPA2B1 and BCL2L1, two genes
highly altered, we identified a potential key regulatory pathway of
hnRNPB1 isoform in apoptosis.
METHODS
Cell Culture
Human HCT116 colorectal carcinoma, OE33 esophageal
adenocarcinoma of the lower esophagus (Barrett’s metaplasia)
and KYSE70 poorly differentiated invasive esophageal squamous
cell carcinoma resected from middle intra-thoracic esophagus
cell lines, were purchased from ATCC. Cells were maintained in
RPMI-1640 medium containing 10% FBS and 1% Glutamine in
a humidified chamber containing 5% CO2.
Extract Preparation
Cotyledon orbiculata plants were purchased from Van den Berg
Garden Village (Western Cape Province, Stellenbosch, South
Africa). The leaves of the plants were removed, washed with
water, cut into small pieces and dried in a ventilated oven at
40◦C for 120 h. The dried leaves were crushed in a blender.
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Two and half (2.5) liters of boiling water were added to 100 g
crushed leaf material and the mixture was stirred for 16 h at room
temperature. This water extract was filtered through Whatman
filter paper (0.45µm pore size), frozen in liquid nitrogen and
subsequently freeze-dried. The dried extract was kept in a
desiccator until further use. Stock solutions of the extract was
prepared in DMSO at 10 mg/ml, which was stored at−20◦C.
Cytotoxicity Assays
The effects of the crude extract of C. orbiculata on viability of
HCT116 colorectal cancer cells, OE33 and KYSE77 esophageal
cancer cells were determined using WST-1 assay. Briefly, a sub-
confluent culture of HCT116, OE33, and KYSE70 were harvested
using trypsin-EDTA and centrifuged at 200 × g for 5min and
re-suspended in growth medium to 5 × 103 cells/ml. A total
of 200 µl of the cell suspension was pipetted into each well of
columns 2–11 of a 96 well culture plate. The same amount of
the growth medium was added to wells of column 1 and 12 to
maintain humidity and minimize the edge effect. The plates were
incubated at 37◦C in a 5% CO2 incubator overnight until the
cells were in the exponential phase of growth. After incubation,
cells were then treated with 6 concentrations of the extract
(100–3.125µg/ml). Each dilution of the test sample was tested
in quadruplicate in each experiment and the experiments were
repeated three times. The plates were again incubated for 48 h
at 37◦C in a 5% incubator. A negative control (untreated cells)
and positive control (cells treated with different concentrations
of cisplatin) were included. After incubation, 20 µL of WST-1
reagent was added to each well and the plates were incubated
for a further 1 h at 37◦C. After incubation with WST-1, the
plates were gently shaken and the amount of WST-1 reduction
was measured immediately by detecting the absorbance using a
microplate reader at a wavelength of 570 nm. The wells in column
1 and 12, containing medium and WST-1 but no cells were used
to blank the microplate reader. The percentage of cell viability
was calculated using the formula below:
%cell viability = (mean absorbance of sample/
mean absorbance of control)× 100.
The LC50 values (lethal concentration at which 50% of the
cells are killed) were calculated as the concentration of the test
sample that resulted in 50% reduction of absorbance compared
to untreated cells.
RNASeq Analysis
RNA was submitted to Deepseq for library preparation and next
generation sequencing was completed on an Illumina NextSeq
(QueenMary University of London). Raw sequence reads in fastq
format were processed for quality (phred scores <30 retained)
and adapter trimmed using the Trimgalore wrapper for FastQC
and Cutadapt (https://github.com/FelixKrueger/TrimGalore).
The resultant quality-controlled reads were aligned to the
GRCh38.83 genome build using STAR (28). Gene expression
was quantified using FeatureCounts (29) and significantly
differentially expressed genes identified using EdgeR and DESeq2
(30, 31). The rMATS tool (32) was used to determine the effect
of the extract differential canonical and de novo splicing. Gene
ontologies and gene set enrichments were determined using
Webgestalt (33) and GSEA (34), respectively.
Polymerase Chain Reaction
To assess the effects of C. orbiculata on splicing of hnRNPA2B1
and BCL2L1 in HCT116, OE33, and KYSE70 cancer cell lines,
cells were treated with varying concentrations of the crude extract
of C. orbiculata (LC50/2, LC50, LC50×2) for 48 h. Following
treatment, total RNA was isolated from treated and untreated
cells using TRI Reagent R© (Sigma). RNA quality and quantity
were measured using a Spectrophotometer (NanoDrop2000,
ThermoFisher Scientific) and samples were stored at ×80◦C.
Reverse transcription polymerase chain reaction (RT-PCR) was
carried out using 1 µg RNA per sample to obtain a constant
amount of cDNA using a Takara PrimeScriptTM RT Reagent Kit
(RR037A). Samples were denatured at 65◦C for 10min, followed
by addition of 1 µl PrimeScript RT enzyme. Thereafter, samples
were incubated at 25◦C for 10min, then 37◦C for 60min followed
by enzyme inactivation at 85◦C for 1min. The cDNA was stored
in−20◦C for future use.
The cDNA samples were then subjected to PCR using
GoTaq R© G2 Green Master Mix (Promega, M7822) and primers
which amplify the different splice variants of hnRNPA2B1 and
Bcl-xl/s (Table 1). GAPDH was used as a control. Primers were
used at final concentration 0.4µM with 1 µl cDNA (∼50 ng).
Samples were denatured at 96◦C for 5min, followed by multiple
cycles (Table 1) of denaturation at 96◦C for 30 s, annealing at
primer specific temperature (Table 1) for 30 s, and extension
at 72◦C for 1min. There was then a final extension step at
72◦C for 10min. Thereafter, the PCR products were subjected
to electrophoresis. Samples were run on 2–3% agarose gels
containing 50 ng/ml ethidium bromide for approximately 1 h at
90V. Gels were visualized using a BioRad Gel DocTM EZ System.
Immunocytochemistry for the Detection of
Cleaved Caspase-3
To detect and quantify activation of caspase-3 in HCT116,
OE33, and KYSE70 cancer cell lines following treatment
with crude extract of C. orbiculata, cells were subjected to
immunofluorescence staining. Cells were seeded at 5,000 cells per
well in a black-walled, glass-bottomed 96 well plate (Corning)
overnight and treated with varying concentrations of the plant
extract based on the calculated LC50 value (LC50/2, LC50,
LC50×2) for each cell line. Staurosporine and cisplatin were used
as positive controls. The cells were washed with sterile 1 X PBS
and fixed with 4% paraformaldehyde (PFA). After fixing, the
cells were permeabilized with 0.2% TritonX, followed by blocking
using 1% BSA for 1 h at room temperature. The cells were
probed for cleaved caspase-3 (Cell Signaling Technology #9661).
The cells were then washed with sterile 1 × PBS, then labeled
with 4µg/mL Alexa Fluor R© 488 goat anti-rabbit IgG secondary
antibody (Product # A-11008, ThermoFisher Scientific, US)
for 30min in the dark. The cell nuclei and cytoskeleton were
identified by counterstaining with DAPI and phalloidin. Samples
were imaged using a Leica TCS SPE confocal microscope. The
images were analyzed using Fiji (Image J 1.0) image analyzer
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TABLE 1 | Primers used to detect the splice variants of hnRNPA2B1 and Bcl-xl/s exposed to extract of Cotyledon orbiculata.
Gene Forward primer Reverse primer PCR conditions
hnRNPA2B1 F1:ATGGAGAAAACTTTAGAAACTGT GTTTCTTCACAGTCACATGGG 35 cycles, annealing 60◦C
F2:ATGGAGAGAGAGAAGGAACAGT
Bcl-xl/s CTGACATCCCAGCTCCACAT AAGAGTGAGCCCAGCAGAAC 35 cycles, annealing 60◦C
GAPDH AATTCCATGGCACCGTCAAG GGTCATGAGTCCTTCCACGA 28 cycles, annealing 60◦C
software to calculate the amount of cleaved caspase-3 in cells,
and estimate cell numbers. The red and blue channels were
threshholded independently and the number of positive CC3
spots counted and divided by the number of DAPI positive
nuclei. An analysis was done blind and automated.
Pladienolide B, a known mRNA splicing inhibitor and
antitumor compound was used as a positive control for RT-PCR
and immunocytochemistry experiments. Cells were treated with
varying concentrations of Pladienolide B (0, 2.5, 5, and 10 nM)
for 48 h.
Knockdown and Over-Expression
The hnRNPB1 specific siRNA was designed using Sigma
MISSION Custom siRNA. The sequence [hnRNPB1
anti sense oligo # 8811245892-000030, UUCCUCUCC
AAAGGAACAG[dT][dT]]. Transfection was performed using
Lipofectamine 2000 (Invitrogen) following the manufacturers
instruction. Briefly, 2 µg of siRNA was mixed with the
transfection reagent and added to HCT116 cells. Non-target
(mock siRNA) and transfection reagent (alone) were included
as controls. A time course of 24, 48, and 72 h was conducted to
establish the time of optimal knockdown then 48 h taken forward
for subsequent experiments. After 48 h, cells were collected for
RNA extraction to be used for RT-PCR, fixed and stained for
cleaved-caspase 3 or tested for effects on viability via cell8/WST-1
as described above. Over expression of GFP-tagged hnRNPB1
(Origene, Rockville MD) in HCT116 cells was achieved through
plasmid transfection with FuGENE R© HD Transfection Reagent
(Promega). HCT116 cells were seeded in a 6 well, tissue culture
plate (150,000 cells/ml) and were allowed to attach. After
attachment, the media was removed, cells were washed in PBS
and trypsinised. Six (6) plates were used, 3 for RNA extraction
at 24, 48 and 72 h after seeding and the remaining 3 for protein
extraction at 24, 48, and 72 h after seeding. They were incubated
at 37 degrees at 5% CO2 during this time. For each plate the cells
in 2 wells were treated with medium, 2 were treated with vector
DNA and 2 with the hnRNPB1 plasmid.
Annexin V and Dead Cell Assay
To confirm whether C. orbiculata induces apoptosis in HCT116,
OE33, and KYSE70 cancer cells, the FITC Annexin V/Dead cell
Apoptosis kit (Invitrogen, ThermoFisher Scientific) was used.
Cells (15× 104 cells/mL) were seeded in 6 well plates and treated
with varying concentrations of the crude extract of C. orbiculata
for 48 h. Cells were harvested, washed two times with ice cold PBS
and adjusted at a density of 1 × 106 cells/sample (500 µL). The
cells were stained with FITCAnnexin-V/PI staining kit according
to the manufacturer’s instructions. The cells were analyzed using
BectonDickinson and Company (FC500) flow cytometer. Results
were analyzed using Kaluza analysis 1.5 software.
RNA Immunoprecipitation
An RNA-binding protein immunoprecipitation (RIP) assay
was conducted using the Magna RIP RNA-Binding Protein
Immunoprecipitation Kit (Millipore) according to the
manufacturer’s protocol. Briefly, HCT116 colorectal cancer
cells were treated with 70µg/ml of C. orbiculata crude extract,
collected and lysed by RIP lysis buffer. Untreated cells were
used as a negative control. Subsequently, 100 µl cell extract was
incubated with RIP buffer containing magnetic beads conjugated
with human anti-hnRNPA2B1 antibody or negative control
normal mouse IgG. Proteinase K was used to digest the protein
and the immunoprecipitated RNA was purified. The isolated
RNA was used for quantitative RT-qPCR analysis of the products
of the BCL2L1, BCL2, MDM2, cMYC, CD44, CDK6, cJUN,
and TXNP genes using LightCycler R© SYBR Green (Roche Life
Science) qPCR kit following the manufacturer instructions. The
selected mRNAs are involved in one way or another in apoptosis.
Statistical Analysis
Data obtained from all experiments were analyzed using
Graphpad Prism version 7.0 statistical software and the values are
expressed as mean ± standard error of mean (SEM). Statistical
significance was considered at p < 0.05 using the One-way
ANOVA with post-hoc Dunnett’s multiple comparisons test. The
asterisk (∗), (∗∗), and (∗∗∗) show p < 0.05, p < 0.01, and p <
0.001, respectively.
RESULTS
C. orbiculata Reduces Viability of HCT116
Colon Cancer Cells, OE33 and KYSE70
Esophageal Cancer Cells
The in vitro antiproliferative activity of the crude leaf extract
of C. orbuculata against HCT116 colorectal carcinoma, OE33
esophageal adenocarcinoma and KYSE70 esophageal squamous
carcinoma cell lines was evaluated using WST-1 cell viability
assays at concentrations ranging from 100 to 3.1µg/ml. The assay
was carried out to determine the effective concentrations for use
in subsequent experiments. The percentage cell viability results
are shown in Figure 1. The WST-1 assay showed that the crude
extract of C. orbiculata dose dependently decreased the viability
of HCT116, OE33 and KYSE70 cancer cell lines with LC50 values
of 64.9, >100, and 36.9µg/ml, respectively (Figure 1A). The
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FIGURE 1 | Decreased cell proliferation in HCT116, OE33, and KYSE70 cancer cells treated with varying concentrations of C. orbiculata for 48 h. The extract reduces
viability of all three cancer cells in a dose dependent manner. (A) Cell viability was determined using the WST-1 cell viability assay (mean ± SEM, n = 3). (B) Percent of
HCT116 cells analyzed by flow cytometry positive for Annexin V and propidium Iodide (PI). (C) Immunocytochemical analysis for apoptosis induction in HCT116, (D)
KYSE70, and (E) OE33 cancer cells treated with varying concentrations of the crude extract of C. orbiculata (calculated from LC50 values) for cleaved caspase-3.
Cells were fixed, permeabilised, and stained with DAPI (blue), phalloidin (green), and Caspase-3-cleavage antibody (red). There was an increase in cleaved caspase-3
per cell number in all three cell lines (e.g., red arrows); an indication of apoptosis induction. (F) Quantitative analysis of images shows a dose depended increase in
cleaved caspase-3 in HCT116 cells. Results presented as caspase-3-cleavage/cell number, ± SEM (n = 3). Scale bar 25 µm. One-way ANOVA, Dunnett’s multiple
comparison test was used, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. See also Supplementary Figure 1 for quantitation of KYSE70 and OE33.
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KYSE670 esophageal cancer cells were most susceptible to the
extract, followed by HCT116 colorectal cancer cells and lastly
OE33 esophageal cancer cells.
C. orbiculata Induces Apoptosis in
HCT116, OE33, and KYSE Cancer Cells
To determine the mechanism of cell death induced by C.
orbiculata extract, we used Annexin-V/PI flow cytometry
(Figure 1B), and found that programmed cell death (apoptosis,
detected by an increase in the proportion of AnnexinV
positive, PI negative cells), was induced after treatment with
35µg/ml or above of the extract. Staurosporine at 10 nM was
used as a positive control. To confirm that this was due to
apoptosis, cleaved caspase-3, a key mediator of programmed
cell death was stained for in HCT116, OE33, and KYSE70
cancer cells by immunocytofluorescence in cancer cells treated
with varying concentrations of the plant extract (LC50×2, LC50,
and LC50/2) (Figures 1C–E). Quantification showed an increase
in the amount of cleaved caspase-3 in all three-cancer cell
lines when comparing treated and untreated cells (Figure 1F,
Supplementary Figure 1). Quantification of the images show a
significant dose dependent increase in caspase-3-cleavage/cell
number with up to a 12-fold increase in caspase-3-cleavage
in HCT116 cancer cells treated with the plant extract when
compared to the untreated cells (p < 0.0001 at 140µg/ml)
and up to a 2-fold increase in both OE33 and KYSE77
(Supplementary Figure 1).
C. orbiculata Drives Alternative Splicing
Pathways
To determine the mechanisms through which C. orbiculata
drives apoptosis, we subjected HCT116 cells to 48 h
treatment with 50µg/ml of the extract, followed by RNA
extraction, and RNASeq and differential gene expression
(Supplementary Table 1) and differential isoform expression
determined (data available on request). Gene ontology analysis
of the RNASeq results based on expression showed that there
was significant upregulation of various pathways, including
movement of cell or subcellular components, inflammatory
response, cell motility, localization of cell, and small molecule
metabolic process at a significance of >10−4, but none of
these pathways were linked to apoptosis or cell death, and the
significance was not strong (gene ontology data available upon
request). GSEA on Hallmarks of Cancer identified apoptosis and
TNFα through NFκB as being significantly altered (Figure 2A).
There was no obvious upregulation of genes involved in a
coordinated manner to induce apoptosis. However, when we
ran an analysis of splicing using rMATS, we identified by
gene ontology analysis that RNA processing events were the
most common pathways activated by C. orbiculata (Figure 2B,
Supplementary Table 2). We examined the top 25 pathways
ranked by False Discovery Rate (FDR) for each of the five
types of splicing event—retained introns (RI), alternative 5′
and 3′ splice sites (A5SS and A3SS), mutually exclusive exons
(MXE) and skipped exons (SE). Thirty-two (32) different
pathways fell into this category. Of the 9 pathways that were
significantly altered for four types of splicing event–5 were
pathways involved in RNA regulation (Figure 2B). There
were significant changes in splicing seen in all 5 categories of
splicing. Of the 10,459 alternatively spliced events, 56% were
skipped exons (Figure 2C). There were substantially fewer exons
where exon inclusion was enhanced by C. orbiculata (45% of
altered splicing events, Figure 2C), than exons inclusion was
decreased by C. orbiculata (55%, Figure 2C), suggesting that C.
orbiculata preferentially causes exon skipping. Retained introns
were also significantly enhanced by C. orbiculata (from 7.6
to 18.4%).
C. orbiculata Modulates Splicing of
hnRNPA2B1 and BCL2L1 in HCT116, OE33,
and KYSE Cancer Cells
Two of the highly regulated genes detected in the splicing
environment that have been linked to apoptosis and RNA
splicing, respectively, were, B Cell Lymphoma 2 like protein 1
(BCL2L1), and hnRNPA2/B1. BCL2L1 encodes for two splice
variants of the protein Bcl-x, a large isoform (Bcl-xl) and
short isoform (Bcl-xs) differentiated by alternative 5′ splice site
selection in exon 2. Inclusion of the distal splice site (i.e., BCl-
xl) was reduced from 97 ± 1.5% to 89 ± 0.5% inclusion (p
= 0.0055). hnRNPA2/B1 codes for two isoforms, hnRNPA2
and hnRNPB1. hnRNPA2B1 exon 2 exclusion (resulting in
B1 expression) was induced by treatment with C. orbiculata,
inclusion of the exon fell from 22 ± 2.4 to 16 ± 1.6% (p =
0.00182). Neither gene was statistically significantly altered when
analyzed by EdgeR, but were significantly altered by DESeq2
analysis (treated was 67% of control, p = 0.004 for BCL2L1
and treated was 54% higher than control for hnRNPA2B1,
p = 4.3 × 10−18). Total transcript levels (in counts) were
BCL2L1 8,128± 1,214 control, 3,692± 327 treated, hnRNPA2B1
16,252 ± 2,783 vs. 28,585 ± 1,494). To verify this effect we
carried out PCR for these two genes on cells treated with
C. orbiculata. As shown in Figure 3, treatment of HCT116,
OE33, and KYSE70 cancer cells with varying concentrations
of C. orbiculata extract results in modulation of splicing of
both hnRNPA2B1 and BCL2L1 (Figure 3A). The extract of C.
orbiculata increased alternative splicing of hnRNPA2B1 in a dose
dependent manner resulting in reduced expression of hnRNPB1
in all 3-cell lines (Figure 3A). The splicing of BCL2L1 was also
affected resulting in an increase in Bcl-xs (Figure 3A). In all cases,
the hnRNPB1 splice variant was found to be downregulated in a
concentration dependent manner whilst Bcl-xs was upregulated
in a concentration dependent manner in cells treated with the
crude extract of C. orbiculata (Figure 3B), consistent with the
RNASeq data. This switch in splicing resulted in a decrease
in the ratio of hnRNPB1 to hnRNPA2 and an increase in the
ratio of Bcl-xs to Bcl-xl in all 3-cancer cell lines (Figure 3B).
These results suggest that C. orbiculata could be acting as a
splicing modulator to induce apoptosis through hnRNPA2/B1
and BCL2L1.
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FIGURE 2 | RNASeq analysis of cells treated with C. orbiculata extract. (A) Gene set enrichment analysis (GSEA) of RNA up or down regulated by treatment.
Apoptotic and cell cycle genes were significantly altered. (B) Gene ontology analysis on altered splicing genes by gene set pathway analysis. Of the 15 pathways with
the most significant change in percent spliced in (PSI) of the gene isoforms for each splice type the number of splice types are shown (i.e., 5 = the pathway was in the
top 15 for all five splice types, 1 = the pathway was in the top 15 for only one splice type. (C) Distribution of gene splicing between the five types for isoforms altered
either way, event included, or event excluded. SE, Skipped exon; MXE, mutually exclusive exons; A5SS, Alternative 5′ splice site; A3SS, alternative 3′ splice site; RI,
retained intron.
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FIGURE 3 | Effects of C. orbiculata on splicing of hnRNPA2B1 and BCL2L1 in HCT116, OE33 and KYSE cancer cells. (A) RT-PCR images and (B) quantitative
analysis of PCR results. Percentage changes in ratio of hnRNPA2B1 and Bxl-xl/s from control. GAPDH was used as a loading control. Quantification demonstrates a
decrease in hnRNPB1, and an increase in Bcl-xs. n = 3, mean ± SEM (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Pladienolide B, Like C. orbiculata,
Modulates Splicing of hnRNPA2B1 and
BCL2L1 to Induce Apoptosis in HCT116
Cancer Cells
To determine whether this specific switch in splicing is a common
mechanism when splicing is altered, we used pladienolide B, a
naturally occurring macrolide with both antitumor activity and
mRNA splicing inhibition activities and measured the effect on
splicing of these two genes. Pladienolide B dose dependently
(0–10 nM) induced apoptosis in HCT116 colon cancer cells as
evident by immunocytochemical analysis of caspase-3-cleavage
(Figure 4A). The macrolide significantly increased caspase-
3-cleavage/cell number up to 3-fold (p < 0.01, Figure 4B).
Additionally, pladienolide B significantly decreased viability
of HCT116 cancer cells at all tested concentrations ranging
from 0 to 10 nM (p < 0.0001, Figure 4C). RT-PCR evaluation
shows that pladienolide B switched splicing of hnRNPA2B1 and
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FIGURE 4 | The splicing inhibitor and antitumor compound Pladienolide B switches splicing of hnRNPA2B1 and BCL2L1 to induce apoptosis in HCT116 colon
cancer cells. (A) Cells were treated with varying concentrations of Pladienolide B for 48 h, fixed, permeabilized, and stained with DAPI (blue), phalloidin (green), and a
Caspase-3-cleavage antibody (CCA) (red). (B) Increased caspase-3-cleavage and (C) Decreased cell viability in HCT-116 cells treated with Pladienolide B. The images
were analyzed using Fiji to calculate the amount of cleaved caspase-3 in cells. mean ± SEM (n = 3). Scale bars 25µm. (D) Effects of Pladienolide B on splicing of
hnRNPA2/B1 and BCL2L1 in HCT116 colon cancer cells using semi quantitative PCR. (E,F) Quantitative analysis of PCR results. Quantification of splice variant
expression demonstrates a decrease in hnRNB1, and an increase in Bcl-xs (n = 3, mean ± SEM), For statistical analysis, One-way ANOVA, Dunnett’s multiple
comparison test and post-hoc test for trend was used, *P < 0.1, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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FIGURE 5 | Knockdown of hnRNPB1 and its effects on splicing of BCL2L1 in HCT116 colon cancer cells. (A) Cells were transfected with 2 µg hnRNPB1 siRNA for
24, 48, and 72 h then RNA was extracted and subjected to RT-PCR. (B,C) Quantification of splice variant expression demonstrated a decrease in hnRNB1, and an
increase in Bcl-xs (n = 3, mean ± SEM), (D) Increased caspase-3-cleavage and decreased cell viability in HCT-116 cells transfected with 2 µg hnRNPB1 siRNA for
48 h. Staurosporine was used as a positive control. DAPI (blue), phalloidin (green), and a Caspase-3-cleavage antibody (CCA) (red). Scale bar = 25µm. (E)
Quantification of the number of cells positive for cleaved caspase-3 mean ± SEM (n = 3). (F) Cell viability. For statistical analysis, One-way ANOVA with Dunnett’s
multiple comparison test and post-hoc test for trend was used, *P < 0.1, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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BCL2L1 (Figure 4D). Quantification of splice variant expression
demonstrates a significant dose dependent decrease in hnRNB1
(p < 0.1), and a significant dose dependent increase in Bcl-
xs (p < 0.1). Interestingly, pladienolide B, unlike C. orbiculata
resulted in an increase in hnRNPA2 and a decrease in Bcl-xl
shown in Figures 4E,F. These results suggest that the switch in
splicing seen by C. orbiculata is consistent with it containing a
naturally occurring splicing factor modulator, but that it could
modulate a different pathway from Pladienolide B. hnRNPA2/B1
is a well-described splicing factor, having been shown to regulate
multiple genes, including VEGF, Nav1.6, ANXA7 and the activity
of kinases such as MEK. However, it is not clear whether
the induction of the pro-apoptotic splice variant of BCL2L1 is
independent of a splice form specific reduction in hnRNPB1 or
a direct consequence of it. We therefore set out to determine
whether hnRNPA2B1 could regulate BCL2L1 splicing.
hnRNPB1 siRNA Modulates Splicing of
BCL2L1, Inhibits Cell Viability and Induces
Apoptosis in HCT116 Cancer Cells
As C. orbiculata reduced the B1 isoform of hnRNPA2B1, we
mimicked this by siRNA knockdown specifically of the hnRNPB1
isoform in HCT116 colon cancer cells. Cells were transfected
with 2 µg of siRNA. The most effective silencing was at 48 h
post transfection (Figures 5A,B). The knockdown of hnRNPB1
also caused a switch in splicing of BCL2L toward Bcl-xs
(Figures 5A,C). Quantification of splice variant expression shows
a decrease in hnRNB1 and an increase in Bcl-xs when comparing
untransfected cells with cells transfected with 2 µg of hnRNPB1
siRNA (Figures 5B,C). This indicates that hnRNPB1 modulates
splicing of BCL2L1. The transfection experiment also showed
that induction of apoptosis in HCT116 colon cancer cells is
replicated by isoform specific knockdown of hnRNPB1 using
siRNA for 24, 48, and 72 h (Figure 5D). Silencing hnRNPB1
resulted in a significant increase in caspase-3-cleavage when
comparing transfected cells to wild type/untransfected cells (p <
0.01, Figure 5E). There was up to a 3-fold increase in caspase-
3-cleavage/cell number in transfected cells. Additionally, using
WST-8/cell 8 cell viability assay, we found that hnRNPB1 siRNA
significantly inhibited cell viability in transfected cells (p < 0.01,
Figure 5F).
C. orbiculata Mediated Cell Death Is
hnRNPB1 Dependent
To confirm that the C. orbiculata extract was inducing apoptosis
through switching splicing from hnRNPB1 we measured the
effect of treatment after over-expression of hnRNPB1 isoform
in HCT116 cells. Fourty eight (35) hours after transfection with
hnRNPB1 plasmid, RNA was extracted, DNAse treated and
subjected to RT-PCR. Figure 6A shows that cell transfected with
the hnRNPB1 plasmid had increased hnRNPB1 expression as
expected. When cells were treated with C. Orbiculata extract
there was a small, significant reduction in the percent of viable
cells as measured by PI-Annexin V flow cytometry, but this was
much less than that induced in the wild type (Figure 6B). This
protection from C. orbiculata extract was due to a decrease in
apoptosis as measured by annexin V positivity in the transfected
cells compared with the wild type (Figure 6C). These results
clearly demonstrate that C. orbiculata extract induces apoptosis
through reduction in the hnRNPB1 isoform.
C. orbiculata Increases
Association/Binding of hnRNPA2B1 to
mRNAs Associated With Apoptosis
Switching splicing of hnRNPA2B1 from the B1 to the A2 isoform
should be able to alter the specific RNAs that the protein
can interact with. We therefore determined the effect of C.
orbiculata crude extracts on association of hnRNPA2B1 with
selected mRNAs known to be either regulated, or involved in
apoptosis (Table 2), by RNA- immunoprecipitation (RIP) assay.
We evaluated the association of hnRNPA2B1 with BCL2L1,
BCL2, MDM2, cMYC, CD44, CDK6, cJUN, and TXNP in
HCT116 colon cancer cells treated with 70µg/ml of the
crude extract. Treatment of HCT116 colon cancer cells with
70µg/ml of C. orbiculata extract resulted in an increase in
the co-precipitation of hnRNPA2B1 with BCL2L1 (Figure 7A),
BCL2 (Figure 7B), MDM2 (Figure 7C), cMYC (Figure 7D),
CD44 (Figure 7E), CDK6 (Figure 7F), and cJUN (Figure 7G)
mRNA. The highest fold enrichment was observed for CDK6
(6,333-fold), followed by cJun (5,947-fold), CD44 (817-fold),
cMYC (595-fold), MDM2 (416-fold), and BCL2L1 (120-fold) in
HCT116 cells treated with C. orbiculata. There was no change
in the binding of TXNP (Figure 7H). These results clearly show
that a reduction in the hnRNPB1 isoform by C. orbiculata extract
changes the interaction with multiple RNAs of genes associated
with apoptosis, indicating that hnRNPA2B1 is a key regulator
of apoptosis through its RNA binding activity and effect on
alternative splicing.
DISCUSSION
Evidence suggests that alternative splicing of mRNA encoding
proteins involved in apoptosis play a major role in the
development and progression of cancer. BCL2L1 is a member
of the BCL-2 gene family, which regulates apoptotic cell death
in various cells. BCL2L1 is alternatively spliced to produce
two isoforms, the longer anti-apoptotic Bcl-xl protein and the
shorter pro-apoptotic Bcl-xs isoform with opposite effects on
apoptosis (36). Bcl-xl is the predominant form in cancer cells,
and its overexpression confers resistance to chemotherapeutic
agents (37). The regulation of BCL2L1 alternative splicing is
of critical importance to the apoptotic process and is highly
relevant to cancer. In a number of cancers and cancer cell lines,
the expression of the anti-apoptotic protein Bcl-xl is increased,
and the ratio of the splice variants is frequently shifted to favor
production of Bcl-xl. Bcl-x regulates the permeability of the
outer membrane of mitochondria. The Bcl-xs splice isoform is
proapoptotic whereas the Bcl-xl isoform is antiapoptotic as it
prevents the release of mitochondrial components that would
lead to apoptosis (38).
Bcl-xl exerts anti-apoptotic activity by forming heterodimers
with both BAX and BAK. The pro-apoptotic function of Bcl-xs is
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FIGURE 6 | Overexpression of hnRNPB1 counteracts the effects of C. orbiculata. (A) Cells were transfected with 2 µg plasmid expressing hnRNPB1 cDNA and then
RNA was extracted and subjected to RT-PCR. Cells were subjected to treatment with C. orbiculata for 48 h and then subjected to Annexin V/PI flow cytometry. (B)
The proportion of viable cells was slightly lower in untreated cells transfected with hnRNPB1 plasmid. However, when treated with C. orbiculata extract there was a
much reduced decrease in viability compared with untransfected cells. (C) The proportion of apoptotic cells was significantly reduced by transfection with hnRNPB1.
One-way ANOVA with Dunnett’s multiple comparison test and post-hoc test for trend was used, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
derived from its capacity to disrupt the complex between BAK
and the voltage-dependent anion channel (VDAC) protein by
interacting with VDAC, thus freeing BAK for activation (39, 40).
The overexpression of Bcl-xl has been shown to protect cells from
TNF-mediated apoptosis and is involved in the inflammatory
response by inhibiting the activation of NF-κB (41). Bcl-
xl has also been shown to have an apoptosis-independent
function in metastasis in pancreatic neuroendocrine tumor and
breast cancer cell lines via nuclear promotion of epithelial-
mesenchymal transition, migration, invasion, and stemness and
in chemoresistance via RAS interaction and influence on EMT
and regulation of cancer-initiating cell (CICs) (42, 43).
The control of splicing of BCL2L1 has not been clearly shown.
Here we identify through knockdown of hnRNP that this results
in a switch in splicing from the anti- (Bcl-xl) to the pro –
(Bcl-xs) apoptotic isoform, and induction of apoptosis showing
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TABLE 2 | Primers used to detect mRNAs hnRNPA2B1-RIP lysates using qPCR
analysis following exposure to extract of Cotyledon orbiculata.
mRNA/gene Primer sequences
BCL2L1 FP 5′-CTGACATCCCAGCTCCACAT 3′
RP 5′ AAGAGTGAGCCCAGCAGAAC 3′
BCL2 FP 5′ CAGGAGAATGGATAAGGCAAA 3′
RP 5′ CCAGCCAGATTTAGGTTCAAA 3′
MDM2 FP 5′ GACTCCAAGCGCGAAAAC 3′
RP 5′ CAGACATGTTGGTATTGCACATT 3′
cMYC FP 5′ AAGGGTGTTGGGTCTCCTG 3′
RP 5′ GTCTGTGTGGCCGCTGTT 3′
CD44 FP 5′ CAACAACACAAATGGCTGGT 3′
RP 5′ CTGAGGTGTCTGTCTCTTTCATCT 3′
CDK6 FP 5′ TGATCAACTAGGAAAAATCTTGGAC3′
RP 5′ GGCAACATCTCTAGGCCAGT 3′
cJun FP 5′ TTCTATGACGATGCCCTCAACGC 3′
RP 5′ GCTCTGTTTCAGGATCTTGGGGTTAC 3′
TXNP FP 5′ ATTCCAACATGGTATTCTTTGAAGT 3′
RP 5′ CCCACTTTTGTCCCTTCTTAAA 3′
that the hnRNPB1 isoform is anti-apoptotic, suggesting that the
A2 isoform is pro-apoptotic. This is consistent with the known
activities of the hnRNPA2/B1 gene, but for the first time identifies
the mechanism through which this acts, binding directly to
BCL2L1 RNA and inducing alternate splicing.
hnRNPA2B1 is implicated to play a direct role in cancer
development, progression, gene expression, and signal
transduction and has been proposed to account for the
oncogenic effects of several types of cancers (44). hnRNPA2B1
belongs to a family of heterogeneous nuclear ribonucleoproteins
(hnRNPs) which are RNA-binding proteins involved in RNA
processing, pre-mRNA splicing, mRNA export, localization,
translation, stability, DNA repair, telomere biogenesis, cell
signaling, and the regulation of gene expression. The levels of
hnRNPA2B1 expression are associated with poor prognosis and
disease progression (45). hnRNPA2B1 is alternatively spliced
by cassette exon exclusion of hnRNPB1, containing exon 2,
constitutes 2–5% of hnRNPA2B1 mRNA with the remainder
alternatively spliced into hnRNPA2 lacking exon 2. Some studies
have demonstrated that hnRNPA2B1 increases the tumorigenic
potential of cells by regulating signal transducer and activator of
transcription 3 (STAT3) and extracellular-signal-regulated kinase
1/2 (ERK1/2) signaling pathway (44). The overexpression of
hnRNPA2 in immortal cells results in malignant transformation,
suggesting that hnRNPA2 is a putative proto-oncogene. Some of
the tumor suppressors and oncogenes regulated by HNRNPA2B1
include c-FLIP, BIN1, and WWOX, and the proto-oncogene
RON (46).
hnRNPB1 has been proposed to be a tumor marker for human
lung cancer (47, 48). hnRNPA2B1 is overexpressed in human
gastric cancer, breast cancer cells, pancreatic cancer cells, lung
cancer cells and several other cancers (35, 44). Interestingly, there
are few studies on the involvement of hnRNPA2 or hnRNPB1
splicing differences in cancer. One report showed overexpression
of hnRNPB1 correlated with the eventual development of lung
cancer (49) and the mRNA is reported to be elevated in lung
cancer tissue and it has been hypothesized to play a role in early
carcinogenesis from a histological study of lung cancer specimens
(50), but there is no clearly defined role of hnRNPB1 in cancers.
Inhibition of splicing has been shown to affect multiple
hallmarks of cancer, including tumor cell proliferation and
apoptosis. Thus, inhibitors of splicing have been intently looked
for over the last 10 years and a few highly effective inhibitors
have been identified. Natural product derivatives of Streptomyces
bacteria such a pladienolide B or herboxidiene or isoginkgetin,
a biflavonoid isolated from Ginko biloba, are inhibitors of the
SF3B1 splicing factor that is required for constitutive splicing.
Such compounds are generally toxic to most cells as they
interfere with all splicing reactions, but tumor cells appear to
be highly dependent on such constitutive splicing and so this
chemotherapeutic approach has been taken into clinical trial
with the SF3b targeting agent E7107 (51). Here we describe
a novel mechanism of inhibiting splicing of key regulatory
genes, in particular hnRNPA2B1 splicing, but also a number
of others identified by RNASeq by an extract from the South
African medicinal plant, Cotyledon orbiculata, or Pig’s Ear.
RNA Seq analysis of cells treated with this extract resulted
in a high concentration of splicing factor, mRNA processing
and mRNA transport mechanisms in the pathway analysis of
alternative splicing variant. We identified that two key regulated
RNA species were hnRNPA2/B1 and BCL2L1. While overall
expression of these RNAs did not appear to be significantly
altered in one analysis it was in another and expression of the
hnRNPA2/B1 gene had increased by 75 ± 5%. Furthermore,
there was a significant switch in isoform expression as revealed
by RNASeq. It is possible that the significant heterogeneity of
transcript/isoform expression observed may mask detection of
significant changes in gene expression, given how transcript
expression is compiled and assigned in gene level quantification.
Future studies should therefore consider the complexity of
transcript heterogeneity induced by Cotyledon orbiculata extract.
Cotyledon orbiculata is a small shrub with fleshy leaves
belonging to the Crassulaceae family. It is widely distributed in
Southern Africa and is used to treat a broad range of ailments.
The leaves have been utilized to treat corns and warts (52, 53),
the sap of the leaves is utilized as drops for toothache and earache;
and is used as a hot poultice for boils and inflammation. The plant
is also used to treat epilepsy (54).
hnRNPA2B1 has been proposed as a therapeutic target for
anticancer therapy, but there are no previous reports of naturally
occurring agents that can switch on targeting splicing to switch
off B1 in colon cancer. The crude extract of C. orbiculata dose
dependently reduced viability of colon and esophageal cancer
cells. We found that the mode of cell death was apoptotic
as evident by caspase-3-cleavage using immunocytochemistry.
Caspase-3 is a major executioner caspase and its activation is a
hallmark of apoptosis and can be used to quantify activators and
inhibitors of the “death cascade” (55). To further confirm that
C. orbiculata induces apoptosis in HCT116 colon cancer cells, we
used Annexin-V-FITC and PI using flow cytometry to quantify
the percentage of viable, apoptotic, late apoptotic and necrotic
cells in HCT116 cells treated with varying concentrations of
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FIGURE 7 | RNA-Binding Protein Immunoprecipitation RIP to detect interaction of hnRNPA2B1 with (A) BCL2L1, (B) BCL2, (C) MDM2, (D) cMYC, (E) CD44, (F)
CDK6, (G) cJun, and (H) TXNP. Lysates prepared from HCT116 colon cancer cells treated with 70µg/ml C. orbiculata were subjected to immunoprecipitation using 5
µg of either a normal mouse IgG or Anti-hnRNPA2B1 antibody. Successful immunoprecipitation of hnRNPA2B1-associated RNA was verified by qPCR using primers
specific for the 8 mRNAs. Results are presented as fold increase relative to IgG. There is a clear significant increase in the binding of 7 (A–G) of the 8 mRNAs to
hnRNPA2B1 in cells treated with the crude plant extract (n = 3, mean ± SEM). For statistical analysis, One-way ANOVA with Dunnett’s multiple comparison test was
used, *P < 0.1, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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C. orbiculata. The extract resulted in an increase in apoptotic cells
as evident by annexin-V-positive cells in the scatter plots and
reduced viable cells when comparing treated cells to untreated
cells at all tested concentrations (56).
We went on to evaluate the effects of C. orbiculata on splicing
of hnRNPA2B1 and BCL2L1 in three-cell lines. The plant extract
switched splicing of hnRNPA2B1, resulting in a decrease in the
expression of hnRNPB1mRNA and an increase in the expression
of hnRNPA2. These changes in the splicing of hnRNPA2B1
resulted in an increase in the ratio of hnRNPA2 to hnRNPB1. We
found that in addition tomodulating the splicing of hnRNPA2B1,
the splicing of BCL2L1 mRNA was also affected in cells treated
with the extract of C. orbiculata. There was a clear increase in
the expression of Bcl-xs isoform and almost no change in the
expression of Bcl-xl in cells treated with varying concentrations
of C. orbiculatawhen compared to untreated cells. These changes
in splicing resulted in an increase in the ratio of Bcl-xs to Bcl-xl.
The effects of C. orbiculata was similar to those of pladienolide B
(14, 15) in that, just like C. orbiculata, pladienolide B switches
splicing of hnRNPA2B1 and BCL2L1 to induce apoptosis in
HCT116 colon cancer cells (Figure 4). However, pladienolide
B also upregulated hnRNPA2, which C. orbiculata extract did
not. While further work would need to be done to confirm this,
including isolation of the active ingredient of C. orbiculata, and
comparison of effects at similar doses, the results do suggest that
the active ingredient in the extract of C orbiculata might not act
similarly to pladienolide B on SF3B.
We found that apoptosis induction is replicated by isoform
specific knockdown of hnRNPB1. RT-PCR revealed that
knockdown of hnRNPB1 can increase Bcl-xs in colon cancer
cells resulting in an increase in caspase-3 cleavage and a decrease
in cell viability, suggesting that hnRNPB1 modulates splicing
of BCL2L1 and is functionally involved in cell proliferation in
HCT116 colon cancer cells. Although the splicing change of
BCL2L1 is small between hnRNPB1 siRNA transfected HCT116
colon cancer cells when compared to the untransfected cell,
the ratio of Bcl-xs/Bcl-xl could be critical for cell survival
as evident by increased caspase-3-cleavage and decreased cell
viability in hnRNPB1 siRNA transfected cells. A delicate balance
between the two isoforms could determine the fate of cells,
which may explain why the regulation of BCL2L1 alternative
splicing is complex (57, 58). To confirm this, we showed that
over-expression of hnRNPB1 blocks the effect of C. orbiculata
extract in HCT116 colon cancer cells, indicating that the
effect was hnRNP splicing dependent, and that hnRNPA2/B1
splicing is the target for the active ingredient(s) in C. orbiculata
extract. The binding of hnRNPA2B1 with BCL2L1 and additional
mRNAs (BCL2, MDM2, cMYC, CD44, CDK6, cJun, and TXNP)
was further confirmed by RNA immunoprecipitation (RIP)
assay. Given there are 10,459 alternative splicing events and
hnRNPA2B1 interacts with multiple apoptotic and cancer genes
it is probable that modulation of many of those genes collectively
contribute to the reduced viability by C. orbiculata extract.
Thus, while these results indicate that C. orbiculata extract
enhances the binding of hnRNPA2B1 to Bclx pre-mRNA, they
also suggest that further mechanisms through which control
of hnRNPA2B1 splicing could regulate apoptosis, for instance
by regulating BCL2, and further work will be required to
quantitatively understand the contribution of Bclx splicing vs.
other mechanisms.
Our interpretations depend upon a number of assumptions
inherent in the methodology we used. These include the
use of agarose gel electrophoresis and densitometry for the
quantification of the relative abundance of the specific isoforms
to confirm the change in splicing induced byC. orbiculata seen by
RNASeq. There are multiple ways to determine RNA expression,
including qRT-PCR, digital droplet PCR, northern blotting, and
RNAse protection assay. Each of these has their advantages and
disadvantages, particularly for examining alternative splicing.
We have used conventional RT-PCR followed by separation
by agarose gel electrophoresis so that both isoforms can be
amplified in the same reaction, removing inter-sample variation,
and comparing the intensity of each band to the other within a
single reaction. While this removes the variation of differential
logarithmic amplification between primers and reactions seen
with qRT-PCR (59) and the potential for mispriming seen in
qRT-PCR (60), it also introduces the potential for saturation
of the PCR reaction, restriction of the dynamic range of the
detectors, and potential for bleed through of signal from closely
related bands. Further work on the level of isoforms to further
confirm the sequencing results would be beneficial, potentially
once the active ingredient in C. orbiculata has been identified,
using digital droplet PCR. The results also assume that the change
in number of transcripts is a consequence of alternative splicing,
rather than differential degradation or enhanced stability of one
isoform over another. This could be further investigated using
RNAse protection assays as previously shown for other isoform
changes (e.g., TIA-1) (61).
CONCLUSION
Our findings on splicing of hnRNPA2B1 and BCL2L1 in HCT116
colon cancer cells and OE33 and KYSE70 esophageal cancer cells
treated with the crude extract of C. orbiculata clearly suggests
that C. orbiculata switches splicing of hnRNPA2B1, which in turn
regulates splicing of BCLX to induce apoptosis in HCT116 colon
cancer cells. It is clear that hnRNPB1 is critical for cell viability
and apoptosis induction. These findings raise the interesting
possibility that targeting hnRNPA2B1 splicing in colon cancer
can be a useful therapeutic strategy to induce apoptosis
and restrain proliferation and tumor progression. This study
provides original insights into the possible use of C. orbiculata,
a South African medicinal plant in the treatment of colon
cancer. Additionally, taken together, our experimental evidence
suggests a possible role of the hnRNPB1 in the tumorigenic
potential of colon cancer. Therefore, there is a possibility of
modulating hnRNPA2B1-regulated genes by manipulating the
level or activity of hnRNPB1. The next step will be to evaluate
how splicing changes impacts these genes and to isolate and
characterize additional phytocompounds form the crude extract
of C. orbiculata.
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